PEAK6
SRPT icon

PEAK6’s Sarepta Therapeutics SRPT Stock Holding History

PEAK6’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,400
Closed -$263K – 3445
2025
Q2 		$263K Sell
15,400
-87,000
-85% -$3.71M ﹤0.01% 2361
2025
Q1 		$6.54M Buy
102,400
+85,800
+517% +$9.03M 0.01% 772
2024
Q4 		$2.02M Buy
+16,600
New +$2.03M ﹤0.01% 1409

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PEAK6's SRPT Position: Q2 2026 in Review

PEAK6 held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 16,315 shares worth $293K. The position accounts for ﹤0.01% of the portfolio, ranked #2160.

PEAK6 first reported a position in SRPT in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.07M in Q1 2025. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • PEAK6 held 16,315 shares of Sarepta Therapeutics worth $293K as of Q2 2026.
  • PEAK6 left its Sarepta Therapeutics share count unchanged in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of PEAK6's portfolio in Q2 2026, its #2160 holding.
  • PEAK6 first reported a position in Sarepta Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • PEAK6's Sarepta Therapeutics position peaked at $2.07M in Q1 2025.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on PEAK6's 13F filing for Q2 2026, filed 13 Aug 2026.